Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.62 |
| ▸ | CA2 | P00918 | 10/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.62 |
| ▸ | CA12 | O43570 | 6/20 | 0.62 |
| ▸ | CA9 | Q16790 | 6/20 | 0.62 |
| ▸ | CA5A | P35218 | 6/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23203210 | 0.83 | BCHE (0.55) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL28116020 | 0.76 | BCHE (0.66) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL10044881 | 0.73 | CA1 (0.73) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL31135818 | 0.73 | CA1 (0.73) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL28037853 | 0.73 | FLT3 (0.67) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL28046686 | 0.73 | BCHE (1.00) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL28522923 | 0.73 | BCHE (0.66) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL30987381 | 0.71 | BCHE (0.62) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL17002383 | 0.71 | BCHE (0.62) | CA1CA2PTGS2CA12CA9 | |
| SCHEMBL28003527 | 0.71 | BCHE (0.57) | CA1CA2PTGS2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | CA1 4141/4885CA2 2434/4885PTGS2 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.